论文部分内容阅读
目的 :探讨艾塞那肽早期2型糖尿病肾病的疗效分析及机制。方法 :将60例2型糖尿病肾病患者随机分为观察组30例与对照组30例,分别采用艾塞那肽及胰岛素(诺和锐30),并同时给予坎地沙坦治疗,治疗3月后检测两组UACR、UAE及血脂水平,结果 :两组治疗后UACR、UAE及血脂均较治疗前显著下降,但观察组下降更为显著(P<0.05)。结果 :艾塞那肽、胰岛素均降低2型糖尿病肾病患者UACR、UAE及血脂水平,但艾塞那肽效果更明显。
Objective: To investigate the efficacy and mechanism of exenatide in the early stage of type 2 diabetic nephropathy. Methods: Sixty patients with type 2 diabetic nephropathy were randomly divided into observation group (n = 30) and control group (n = 30). Exenatide and insulin (Novo-Rui 30) were given separately and treated with candesartan for 3 months After treatment, UACR, UAE and blood lipids were measured. The results showed that the UACR, UAE and blood lipids decreased significantly in both groups after treatment, but the decrease in the observation group was more significant (P <0.05). Results: Both exenatide and insulin reduced UACR, UAE and blood lipids in patients with type 2 diabetic nephropathy, but exenatide was more effective.